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Background: Effectiveness of a drug is a key concept dependent on efficacy, safety, and 
tolerability. Time to discontinuation of treatment is also representative of effectiveness. 
We investigated differences in treatment discontinuation among newly started second-generation 
antipsychotics in the clinical setting.
Methods: Using a retrospective cohort study design, we screened all outpatients (n = 7936) 
who visited the Shioiri Mental Clinic between July 1, 2008 and June 30, 2010. We identified 
a cohort of patients (n = 703) diagnosed with schizophrenia or schizoaffective disorder and 
calculated the time to discontinuation of each second-generation antipsychotic.
Results: Of the 703 patients, 149 were newly treated with aripiprazole, 67 with blonanserin, 
95 with olanzapine, 36 with quetiapine, 74 with perospirone, and 120 with risperidone. The time 
to discontinuation for all causes was significantly longer for aripiprazole than for blonanserin, 
olanzapine, and risperidone. In addition, aripiprazole tended to be continued for longer than 
quetiapine and perospirone, but these differences were not significant.
Conclusion: Aripiprazole may be considered the best available option for long-term treatment 
of patients with schizophrenia or schizoaffective disorder.
Keywords: retrospective study, second-generation antipsychotics, effectiveness, treatment 
continuation, schizophrenia, aripiprazole
Introduction
Second-generation (atypical) antipsychotics are first-line treatment for schizophrenia 
in the clinical setting at present because they are better tolerated than first-generation 
(typical) antipsychotics and are subjectively preferred by patients.1,2
Treatment effectiveness has become a key concept for evaluating long-term 
pharmacotherapy in schizophrenia.3–5 Effectiveness is considered when integrat-
ing the parameters of efficacy, safety, and tolerability by both the patient and the 
clinician. Rates of continuation or discontinuation of treatment serve as appropri-
ate surrogate parameters of effectiveness.4–7 There are several reports of time to 
treatment discontinuation among antipsychotics. The Clinical Antipsychotics 
Trials of Intervention Effectiveness (CATIE) schizophrenia study is the most 
famous of the comparative studies of antipsychotic effectiveness.4,5 However, few 
naturalistic studies have evaluated differences in effectiveness between the avail-
able second-generation antipsychotics. We undertook this retrospective study to 
investigate treatment continuation for the second-generation antipsychotics in the 
clinical setting.
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Materials and methods
Study design
The second-generation antipsychotics investigated were 
aripiprazole, blonanserin, olanzapine, perospirone, quetia-
pine, and risperidone. These were the agents available in 
Japan between July 1, 2008 and June 30, 2010, when we 
conducted this study. Using a retrospective cohort design, 
we screened all outpatients who visited the Shioiri Mental 
Clinic during this time period. Shioiri Mental Clinic is 
a psychiatric outpatient office in Yokosuka in Japan that 
employs six psychiatrists. All patients were diagnosed using 
the International Classification of Diseases, Tenth Revision 
(ICD-10) by the treating psychiatrists in a routine clinical 
setting and not on the basis of a structured interview. The 
treating psychiatrists also judged whether treatment with 
the antipsychotic should be continued on the basis of patient 
response.
From medical records we formed a cohort of patients 
diagnosed with schizophrenia (F20) or schizoaffective 
disorder (F25). We then evaluated groups of patients 
who were newly treated with each second-generation 
antipsychotic in the cohort. We included not only patients 
who were newly started on a single drug but also those 
undergoing adjunctive treatment with a second-generation 
antipsychotic drug.
To assess rates of continuation or discontinuation and 
adherence or nonadherence, we retrospectively reviewed 
medical records between the date of treatment initiation 
and the latest visit in June 2011. Treatment discontinuation 
was deemed to have occurred if the following criteria were 
met: the antipsychotic drug was discontinued because of 
all causes; the patient did not visit the clinic as a result of 
dropout, being admitted to the hospital, moving to another 
hospital, or death; and duration without medication were over 
14 consecutive days. Treatment continuation was defined as 
continuation of the antipsychotic drug until the latest visit 
day in June 2011. We counted the time (days) until discon-
tinuation of treatment due to all causes until the latest visit 
day in June 2011.
Statistical analysis
Time until discontinuation of treatment was estimated using 
a Kaplan–Meier survival analysis. Treatment groups were 
compared using the Cox’s proportional hazards regression 
model. P values ,0.05 were considered significant. All 
analyses were performed using Excel Tokei 2010 for Win-
dows, Version 1.04 (Social Survey Research Information 
Company Ltd, Tokyo, Japan).
Results
Of the 7936 outpatients who visited Shioiri Mental Clinic 
between July 1, 2008 and June 30, 2010, 703 were diagnosed 
with schizophrenia or schizoaffective disorder by ICD-10. Of 
these 703 patients, 149 were newly treated with aripiprazole, 
67 with blonanserin, 95 with olanzapine, 36 with quetiapine, 
74 with perospirone, and 120 with risperidone. Table 1 lists 
the characteristics of patients treated with second-generation 
antipsychotics. These data indicate that the average daily 
antipsychotic doses in Japanese patients are somewhat lower 
than those in Western patients. One of the possible reasons is 
that Japanese patients have a smaller build and a lower body 
weight in comparison with Western patients.
Discontinuation outcomes are presented in Figure 1 
and Table 2. Time to discontinuation due to all causes was 
significantly longer for aripiprazole than for blonanserin 
(hazard ratio [HR], 0.63; P = 0.008), olanzapine (HR, 0.62; 
P = 0.003), and risperidone (HR, 0.58; P , 0.001). Although 
there were no significant differences between aripiprazole 
and quetiapine or between aripiprazole and perospirone, 
aripiprazole tended to be continued for longer than quetiapine 
(HR, 0.74; P = 0.092) or perospirone (HR, 0.68; P = 0.086, 
Figure 1). There were no significant differences between any 
of the second-generation antipsychotics except in comparison 
with aripiprazole (Table 2).
Discussion
The primary outcome measure in this study was all causes 
of treatment discontinuation, which is a global measure 
of the effectiveness of a drug in the clinical setting.4–7 
  Treatment continuation is affected by multiple factors, such 
as the efficacy, safety, and tolerability of the drug, as well 
as the preference of the patient and caregiver. In this study, 
  aripiprazole had a significantly longer time to discontinuation 
than blonanserin, olanzapine, or risperidone, and showed 
a tendency to be continued for longer than quetiapine or 
  perospirone. Therefore, aripiprazole might be more effective 
than the other five second-generation antipsychotics.
A possible reason for the superiority of aripiprazole in treat-
ment continuation may be related to its unique pharmacological 
profile.2 Aripiprazole acts as a partial agonist at dopaminergic 
D2
8 and serotoninergic 5-HT1A
9 receptors and as an antagonist 
at 5-HT2A receptors.10 It also shows low affinity for histamin-
ergic H1 and muscarinic cholinergic receptors.2,10 Because of 
this pharmacological profile, it has a low propensity to cause 
extrapyramidal symptoms, weight gain, metabolic disrup-
tion, hyperprolactinemia, sedation, or prolongation of the QT 
interval,10,11 and has little effect on   psychosocial   functioning.12 
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Table 1 Information on patients treated with second-generation antipsychotics
Aripiprazole 
(n = 149)
Blonanserin 
(n = 67)
Olanzapine 
(n = 95)
Perospirone 
(n = 36)
Quetiapine 
(n = 74)
Risperidone 
(n = 120)
Gender
  Female, n (%) 91 (61.1) 35 (52.2) 55 (57.9) 23 (63.9) 44 (59.5) 71 (59.2)
  Male, n (%) 58 (38.9) 32 (47.8) 40 (42.1) 13 (36.1) 30 (40.5) 49 (40.8)
Age (years)
  Mean (SD) 43.5 (14.8) 45.6 (15.2) 49.7 (18.7) 43.9 (14.8) 50.5 (16.7) 45.1 (16.1)
  Median 41 42 43 40 45 42
Disease duration (years)
  Mean (SD) 14.7 (10.5) 14.7 (10.2) 12.7 (9.8) 15.5 (9.0) 17.7 (11.8) 15.0 (11.7)
  Median 12.0 11.0 11.0 13.5 13.5 12.0
Mean modal dose (mg per day)
  Mean (SD) 15.9 (10.4) 9.3 (4.6) 8.5 (6.4) 15.6 (13.8) 275.9 (164.7) 3.3 (4.9)
  Median 12 8 5 10 250 2
Abbreviation: SD, standard deviation.
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Figure 1 Kaplan–Meier analysis of time to discontinuation of second-generation antipsychotics.
Aripiprazole is well tolerated13,14 and is more often preferred 
by patients and caregivers.15 Therefore, aripiprazole may be 
appropriate for long-term treatment of patients with schizo-
phrenia or schizoaffective disorder.
Our study had several limitations. First, it was   retrospective 
in nature and undertaken in a single outpatient office setting. 
Generalizing these results to inpatient or outpatient settings 
in hospitals may not be appropriate. A prospective, multi-
center, and naturalistic study needs to be conducted in order 
to confirm our findings. Second, we were unable to evaluate 
several cofactors that influence both the course of psychosis 
and medication adherence, such as years of treatment with 
other antipsychotics, age at onset of psychosis, duration of 
possible untreated psychosis, and neuropsychological per-
formance. Third, the analysis in this study included not only 
monotherapy, but also adjunctive treatment. Strictly speak-
ing, the time to discontinuation obtained in our study may 
not necessarily indicate effectiveness of second-generation 
antipsychotic drugs. Fourth, detailed reasons for treatment 
discontinuation were not evaluated. In a future study, the 
reasons for discontinuation should be classified according to 
lack of efficacy, intolerable adverse effects, or a decision by 
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the patient to understand better the differences in effective-
ness among second-generation antipsychotics. Fifth, in this 
study, continuation/discontinuation of treatment and adher-
ence/nonadherence were assessed by patient response and not 
by objective data such as antipsychotic blood levels. Recall 
bias and validity of information from patients may influence 
the evaluation of antipsychotic effectiveness.
Despite these limitations, our finding of differences in 
effectiveness among second-generation antipsychotics pro-
vides important information, helping clinicians to choose 
treatments that are appropriate for patients with schizophrenia 
or schizoaffective disorder.
Conclusion
We retrospectively evaluated the effectiveness of second-
generation antipsychotics by comparing their time to 
  discontinuation. Aripiprazole might be considered the best 
of the available options for long-term treatment of patients 
with schizophrenia or schizoaffective disorder.
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